Smith & Nephew Admits Additional Shares From Employee Schemes to London Market
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Smith & Nephew Snats ( (SNN) ).
On May 22, 2026, Smith & Nephew plc reported the admission to trading of an additional 8,905 ordinary shares of USD 0.20 each on the Main Market of the London Stock Exchange. These new shares, fully fungible with existing stock, were issued between March 23 and May 21, 2026 under the company’s employee share schemes.
Following this small incremental issuance, Smith & Nephew’s total share capital rose to 877,733,750 ordinary shares, of which 26,452,529 are held in treasury. The move underscores the company’s continued use of equity-based compensation, with limited impact on overall share capital but ongoing implications for dilution and employee alignment for existing investors.
The most recent analyst rating on (SNN) stock is a Hold with a $30.00 price target. To see the full list of analyst forecasts on Smith & Nephew Snats stock, see the SNN Stock Forecast page.
Spark’s Take on SNN Stock
According to Spark, TipRanks’ AI Analyst, SNN is a Outperform.
The score is driven primarily by improving financial performance (margin and cash flow rebound) and supportive technicals (price above major moving averages with positive momentum). Valuation is only average at a 22.7 P/E, while the earnings call adds confidence via upbeat 2026 growth/profit guidance but flags meaningful near-term tariff and reimbursement headwinds.
To see Spark’s full report on SNN stock, click here.
More about Smith & Nephew Snats
Smith & Nephew plc is a global medical technology company headquartered in Watford, England, best known for its orthopaedics, sports medicine and advanced wound management products. Its ordinary shares are listed on the Main Market of the London Stock Exchange, providing access to international investors focused on the healthcare and medtech sectors.
The group’s capital structure includes a large base of ordinary shares with a portion held in treasury, supporting ongoing use of share-based incentive schemes for employees. These schemes are routinely serviced through admissions of new shares to trading, helping align staff interests with long-term shareholder value without materially altering control of the company.
Average Trading Volume: 1,038,752
Technical Sentiment Signal: Buy
Current Market Cap: $13.1B
For a thorough assessment of SNN stock, go to TipRanks’ Stock Analysis page.
